Identification and characterization of novel mutations of the aspartoacylase gene in non‐Jewish patients with Canavan disease
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Canavan disease, an inherited leukodystrophy, is caused by mutationsin the aspartoacylase (ASPA) gene. It is most common among children of Ashkenazi Jewish descent but has been diagnosed in many diverse ethnic groups.Two mutations comprise the majority of mutant alleles in Jewish patients, while mutations in the ASPA gene among non‐Jewish patients are different and more diverse. In the present study, the ASPA gene was analysed in 22 unrelated non‐Jewish patients with Canavan disease, and 24 different mutations were found. Of these, 14 are novel, including five missense mutations (E24G, D68A, D249V, C152W, H244R), two nonsense mutations (Q184X, E214X), three deletions (923delT, 33del13, 244delA), one insertion mutation (698insC), two sequence variations in one allele ([10T > G; 11insG]), an elimination of the stop codon (941A > G, TAG → TGG, X314W), and one splice acceptor site mutation (IVS1 − 2A > T). The E24G mutation resulted in substitution of an invariable amino acid residue (Glu) in the first esterase catalytic domain consensus sequence. The IVS1 − 2A > T mutation caused the retention of 40 nucleotides of intron 1 upstream of exon 2. The results of transient expression of the mutant ASPA cDNA containing these mutations in COS‐7 cells and assays for ASPA activity of patient fibroblasts indicated that these mutations were responsible for the enzyme deficiency. In addition, patients with the novel D249V mutation manifested clinically at birth and died early. Also, patients with certain other novel mutations, including C152W, E214X, X314W, and frameshift mutations in both alleles, developed clinical manifestations at an earlier age than in classical Canavan disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease
Kaul, R., Ping Gao, G., Balamurugan, K., & Matalon, R. (1993) · Nature Genetics · doi:10.1038/ng1093-118 · Cited by 221 · cited 14×
“The human aspartoacylase gene is located on chromosome 17p13ter, and consists of six exons spanning about 30 kb of genomic DNA that encodes a protein of 313 amino acids (Kaul et al 1993, 1994a).”
Influential
Cited by
N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology
Moffett, J. R., Ross, B., Arun, P., Madhavarao, C. N., & Namboodiri, A. M. A. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.12.003 · Cited by 1,405
Long-term follow-up after gene therapy for canavan disease
Leone, P., Shera, D., McPhee, S. W. J., Francis, J. S., Kolodny, E. H., Bilaniuk, L. T., Wang, D.-J., Assadi, M., Goldfarb, O., Goldman, H. W., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003454 · Cited by 307
“Most ASPA mutations in Canavan disease are functionally equivalent (44) with nearly total loss of enzyme activity, and patients with typical mutations are uniformly severely affected.”
BackgroundSelf-citationTraka, M., Wollmann, R. L., Cerda, S. R., Dugas, J., Barres, B. A., & Popko, B. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1490-08.2008 · Cited by 82
“It generates a Q193X change, resulting in the premature termination of the protein at D192 and the subsequent truncation of its last 120 aa, a domain that includes the amino acid sequence motifs DCTV and VNEAAYY that are involved in Aspa’s catalytic activity (Kaul et al., 1993; Zeng et al., 2002).”
BackgroundClinical Applications Involving CNS Gene Transfer
Kantor, B., McCown, T., Leone, P., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00002-0 · Cited by 74
“CD occurs in all ethnic groups (Zeng et al., 2002), but it is present with high frequency (carrier rate of 1:40) in Ashkenazi Jewish descendants; two mutations (E285A and Y231X) account for almost all cases of CD in this population (Matalon, Michals, & Kaul, 1995).”
BackgroundSelf-citation
Metadata
- Authors
- Zeng, B. J., Wang, Z. H., Ribeiro, L. A., Leone, P., De Gasperi, R., Kim, S. J., Raghavan, S., Ong, E., Pastores, G. M., & Kolodny, E. H.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2002-11
- Volume
- 25
- Issue
- 7
- Pages
- 557-570
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W1557913677
- Cited by
- 64
- References
- 1
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification and characterization of novel mutations of the aspartoacylase gene in non‐Jewish patients with Canavan disease. https://app.cochat.ai/papers/10.1023/a:1022091223498
- The paper
- Zeng, B. J., Wang, Z. H., Ribeiro, L. A., Leone, P., De Gasperi, R., Kim, S. J., Raghavan, S., Ong, E., Pastores, G. M., & Kolodny, E. H. (2002). Identification and characterization of novel mutations of the aspartoacylase gene in non‐Jewish patients with Canavan disease. Journal of Inherited Metabolic Disease. https://doi.org/10.1023/a%3A1022091223498
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.